Shire earnings jump but sales disappoint

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Product sales in the three months to end-March 2013 were up 1.0% to $1.1bn against a strong set of comparatives from the equivalent period in 2012, but this was less than analysts were expecting.

Sales of Replagal for sufferers of Fabry disease fell 15% due to issues with shipments and competition, while the restructuring of the sales and marketing model for Dermagraft foot ulcer treatment saw its sales fall 62%.

Compensating for these falls, Dublin-headquartered Shire enjoyed particularly strong performances from Vyvanse for children with attention-deficit disorder (ADHD), hyperactivity treatment Intuniv and Lialda for colitis, leading to group earnings advancing 10% to $1.63 per share on a non-GAAP basis and generating $257m of cash during the quarter.

As he set out his strategy for Shire's future, new Chief Executive Officer Flemming Ornskov said: "Shire has consistently delivered growth significantly above the industry levels of mid single digit and we intend that this will be the case in the future."

Ornskov's growth strategy is to sharpen the group's focus on "commercial excellence" of currently marketed products and "pipeline innovation" through research and development and business development.

Broker Jefferies notes that management are confident in meeting earnings forecasts of $6.67 earnings per ADS, but are now targeting lower sales growth due to weaker Replagal and Dermagraft.

The broker said: "As a growth story we believe lower top-line momentum [will] drive stock weakness, but longer-term valuation and pipeline drive our 'buy'."

Shares in Shire were down 6.4% at 1,890p at 15:20 on the day of the announcement.

OH

Recommended

Which assets will benefit as the “jam tomorrow” bubble pops?
Investment strategy

Which assets will benefit as the “jam tomorrow” bubble pops?

With tech stocks, cryptocurrencies and many other “long duration” investments crashing hard, the “jam tomorrow” bubble looks to be bursting. John Step…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022
Seven cheap defence stocks to buy now
Share tips

Seven cheap defence stocks to buy now

We’ve got used to a world without war between major powers, but that era is coming to an end as Russia threatens Ukraine and China eyes Taiwan. Buy de…
21 Jan 2022

Most Popular

Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022